Name | Number of supported studies | Average coverage | |
---|---|---|---|
fibroblast | 35 studies | 27% ± 10% | |
pericyte | 33 studies | 34% ± 13% | |
smooth muscle cell | 25 studies | 31% ± 11% | |
macrophage | 25 studies | 33% ± 17% | |
connective tissue cell | 11 studies | 31% ± 14% | |
microglial cell | 11 studies | 30% ± 10% | |
myofibroblast cell | 10 studies | 29% ± 12% | |
conventional dendritic cell | 10 studies | 19% ± 3% | |
dendritic cell | 8 studies | 20% ± 4% | |
myeloid cell | 7 studies | 33% ± 7% | |
leukocyte | 6 studies | 22% ± 5% | |
astrocyte | 6 studies | 28% ± 7% | |
endothelial cell | 5 studies | 27% ± 4% | |
alveolar macrophage | 5 studies | 22% ± 4% | |
mesothelial cell | 4 studies | 33% ± 18% | |
basal cell | 4 studies | 21% ± 4% | |
mononuclear phagocyte | 3 studies | 39% ± 21% | |
glial cell | 3 studies | 21% ± 5% | |
muscle cell | 3 studies | 33% ± 12% | |
adventitial cell | 3 studies | 33% ± 19% | |
Schwann cell | 3 studies | 28% ± 8% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
lung | 3 studies | 23% ± 2% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
breast | 100% | 6399.65 | 459 / 459 | 97% | 41.00 | 1084 / 1118 |
thymus | 99% | 4142.36 | 648 / 653 | 95% | 33.04 | 576 / 605 |
lung | 99% | 5348.11 | 575 / 578 | 93% | 35.01 | 1075 / 1155 |
prostate | 99% | 4704.06 | 242 / 245 | 90% | 22.39 | 451 / 502 |
ovary | 99% | 5477.37 | 178 / 180 | 89% | 25.01 | 381 / 430 |
uterus | 100% | 7339.12 | 170 / 170 | 83% | 34.52 | 382 / 459 |
intestine | 99% | 7102.90 | 952 / 966 | 79% | 22.99 | 414 / 527 |
esophagus | 86% | 5925.46 | 1244 / 1445 | 89% | 30.21 | 163 / 183 |
bladder | 100% | 7444.90 | 21 / 21 | 73% | 28.38 | 368 / 504 |
brain | 72% | 1901.16 | 1895 / 2642 | 99% | 45.17 | 701 / 705 |
skin | 98% | 10758.00 | 1768 / 1809 | 72% | 37.96 | 339 / 472 |
stomach | 81% | 4045.65 | 290 / 359 | 84% | 27.55 | 241 / 286 |
kidney | 62% | 1694.89 | 55 / 89 | 92% | 63.47 | 825 / 901 |
adrenal gland | 98% | 3581.25 | 254 / 258 | 51% | 9.73 | 118 / 230 |
blood vessel | 100% | 12793.91 | 1335 / 1335 | 0% | 0 | 0 / 0 |
adipose | 100% | 9050.84 | 1203 / 1204 | 0% | 0 | 0 / 0 |
pancreas | 6% | 100.48 | 21 / 328 | 93% | 52.58 | 166 / 178 |
spleen | 97% | 4683.01 | 233 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 89% | 25.36 | 40 / 45 |
heart | 87% | 3144.53 | 751 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 45% | 7.17 | 36 / 80 |
lymph node | 0% | 0 | 0 / 0 | 45% | 7.97 | 13 / 29 |
muscle | 39% | 781.44 | 311 / 803 | 0% | 0 | 0 / 0 |
liver | 6% | 110.25 | 13 / 226 | 29% | 5.61 | 119 / 406 |
peripheral blood | 0% | 1.45 | 1 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0035457 | Biological process | cellular response to interferon-alpha |
GO_0007283 | Biological process | spermatogenesis |
GO_0001974 | Biological process | blood vessel remodeling |
GO_0006954 | Biological process | inflammatory response |
GO_0048549 | Biological process | positive regulation of pinocytosis |
GO_0007169 | Biological process | cell surface receptor protein tyrosine kinase signaling pathway |
GO_0001779 | Biological process | natural killer cell differentiation |
GO_0051250 | Biological process | negative regulation of lymphocyte activation |
GO_0045087 | Biological process | innate immune response |
GO_0007165 | Biological process | signal transduction |
GO_0001961 | Biological process | positive regulation of cytokine-mediated signaling pathway |
GO_0048678 | Biological process | response to axon injury |
GO_0007275 | Biological process | multicellular organism development |
GO_1903902 | Biological process | positive regulation of viral life cycle |
GO_0001764 | Biological process | neuron migration |
GO_0031100 | Biological process | animal organ regeneration |
GO_0042698 | Biological process | ovulation cycle |
GO_0097028 | Biological process | dendritic cell differentiation |
GO_0051649 | Biological process | establishment of localization in cell |
GO_0030168 | Biological process | platelet activation |
GO_0032940 | Biological process | secretion by cell |
GO_0034101 | Biological process | erythrocyte homeostasis |
GO_0033674 | Biological process | positive regulation of kinase activity |
GO_0046718 | Biological process | symbiont entry into host cell |
GO_0032825 | Biological process | positive regulation of natural killer cell differentiation |
GO_0051402 | Biological process | neuron apoptotic process |
GO_0060068 | Biological process | vagina development |
GO_0043066 | Biological process | negative regulation of apoptotic process |
GO_0034446 | Biological process | substrate adhesion-dependent cell spreading |
GO_0006909 | Biological process | phagocytosis |
GO_0071222 | Biological process | cellular response to lipopolysaccharide |
GO_0021885 | Biological process | forebrain cell migration |
GO_0048010 | Biological process | vascular endothelial growth factor receptor signaling pathway |
GO_0032689 | Biological process | negative regulation of type II interferon production |
GO_0010936 | Biological process | negative regulation of macrophage cytokine production |
GO_0051897 | Biological process | positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction |
GO_0007399 | Biological process | nervous system development |
GO_0032720 | Biological process | negative regulation of tumor necrosis factor production |
GO_0043524 | Biological process | negative regulation of neuron apoptotic process |
GO_2000669 | Biological process | negative regulation of dendritic cell apoptotic process |
GO_0048469 | Biological process | cell maturation |
GO_0016477 | Biological process | cell migration |
GO_0070301 | Biological process | cellular response to hydrogen peroxide |
GO_0097350 | Biological process | neutrophil clearance |
GO_0005615 | Cellular component | extracellular space |
GO_0043235 | Cellular component | receptor complex |
GO_0005886 | Cellular component | plasma membrane |
GO_0070062 | Cellular component | extracellular exosome |
GO_0009986 | Cellular component | cell surface |
GO_0015629 | Cellular component | actin cytoskeleton |
GO_0043231 | Cellular component | intracellular membrane-bounded organelle |
GO_0043548 | Molecular function | phosphatidylinositol 3-kinase binding |
GO_0004713 | Molecular function | protein tyrosine kinase activity |
GO_0032036 | Molecular function | myosin heavy chain binding |
GO_0001786 | Molecular function | phosphatidylserine binding |
GO_0001618 | Molecular function | virus receptor activity |
GO_0004714 | Molecular function | transmembrane receptor protein tyrosine kinase activity |
GO_0005524 | Molecular function | ATP binding |
GO_0005515 | Molecular function | protein binding |
Gene name | AXL |
Protein name | Tyrosine-protein kinase receptor UFO (EC 2.7.10.1) (AXL oncogene) receptor protein-tyrosine kinase (EC 2.7.10.1) |
Synonyms | UFO |
Description | FUNCTION: Receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding growth factor GAS6 and which is thus regulating many physiological processes including cell survival, cell proliferation, migration and differentiation. Ligand binding at the cell surface induces dimerization and autophosphorylation of AXL. Following activation by ligand, AXL binds and induces tyrosine phosphorylation of PI3-kinase subunits PIK3R1, PIK3R2 and PIK3R3; but also GRB2, PLCG1, LCK and PTPN11. Other downstream substrate candidates for AXL are CBL, NCK2, SOCS1 and TNS2. Recruitment of GRB2 and phosphatidylinositol 3 kinase regulatory subunits by AXL leads to the downstream activation of the AKT kinase. GAS6/AXL signaling plays a role in various processes such as endothelial cell survival during acidification by preventing apoptosis, optimal cytokine signaling during human natural killer cell development, hepatic regeneration, gonadotropin-releasing hormone neuron survival and migration, platelet activation, or regulation of thrombotic responses. Also plays an important role in inhibition of Toll-like receptors (TLRs)-mediated innate immune response. .; FUNCTION: (Microbial infection) Acts as a receptor for lassa virus and lymphocytic choriomeningitis virus, possibly through GAS6 binding to phosphatidyl-serine at the surface of virion envelope. .; FUNCTION: (Microbial infection) Acts as a receptor for Ebolavirus, possibly through GAS6 binding to phosphatidyl-serine at the surface of virion envelope. .; FUNCTION: (Microbial infection) Promotes Zika virus entry in glial cells, Sertoli cells and astrocytes . Additionally, Zika virus potentiates AXL kinase activity to antagonize type I interferon signaling and thereby promotes infection . Interferon signaling inhibition occurs via an SOCS1-dependent mechanism . . |
Accessions | P30530 ENST00000301178.9 [P30530-1] ENST00000359092.7 [P30530-2] ENST00000593513.1 M0R0W6 |